

Adele K Fielding

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4668018/publications.pdf>

Version: 2024-02-01

126
papers

9,672
citations

94415

37
h-index

37202

96
g-index

130
all docs

130
docs citations

130
times ranked

9145
citing authors

#	ARTICLE	IF	CITATIONS
1	Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2017, 376, 836-847.	27.0	1,443
2	Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 57-66.	10.7	1,031
3	Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. <i>Blood</i> , 2007, 109, 944-950.	1.4	716
4	In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). <i>Blood</i> , 2008, 111, 1827-1833.	1.4	702
5	Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. <i>Blood</i> , 2007, 109, 3189-3197.	1.4	655
6	Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. <i>Nature</i> , 2007, 447, 966-971.	27.8	355
7	Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 1795-1802.	1.6	348
8	T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). <i>Blood</i> , 2009, 114, 5136-5145.	1.4	346
9	UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. <i>Blood</i> , 2014, 123, 843-850.	1.4	321
10	Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. <i>Blood</i> , 2009, 113, 4489-4496.	1.4	257
11	Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age. <i>British Journal of Haematology</i> , 1997, 98, 512-519.	2.5	230
12	Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. <i>Blood</i> , 2001, 97, 3746-3754.	1.4	223
13	Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2016, 7, 13331.	12.8	218
14	Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. <i>British Journal of Haematology</i> , 2012, 157, 463-471.	2.5	161
15	International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. <i>Haematologica</i> , 2016, 101, 1524-1533.	3.5	154
16	Activated stromal cells transfer mitochondria to rescue acute lymphoblastic leukemia cells from oxidative stress. <i>Blood</i> , 2019, 134, 1415-1429.	1.4	148
17	Minimal residual disease is a significant predictor of treatment failure in non-T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. <i>British Journal of Haematology</i> , 2010, 148, 80-89.	2.5	147
18	IGH@ Translocations, CRLF2 Dereglulation, and Microdeletions in Adolescents and Adults With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 3100-3108.	1.6	120

#	ARTICLE	IF	CITATIONS
19	Donor Lymphocyte Infusions Modulate Relapse Risk in Mixed Chimeras and Induce Durable Salvage in Relapsed Patients After T-Cell-Depleted Allogeneic Transplantation for Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 971-978.	1.6	117
20	Strength of Envelope Protein Interaction Modulates Cytopathicity of Measles Virus. <i>Journal of Virology</i> , 2002, 76, 5051-5061.	3.4	111
21	Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2019, 54, 798-809.	2.4	106
22	<i>t(12;21)(p13;q22)</i> Translocations Are Prevalent in Teenagers and Young Adults With Acute Lymphoblastic Leukemia and Are Associated With a Poor Outcome. <i>Journal of Clinical Oncology</i> , 2014, 32, 1453-1462.	1.6	87
23	Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1739-1751.	4.1	87
24	An oncolytic measles virus engineered to enter cells through the CD20 antigen. <i>Molecular Therapy</i> , 2003, 7, 62-72.	8.2	86
25	Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression. <i>Cancer Research</i> , 2003, 63, 6463-8.	0.9	82
26	G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. <i>British Journal of Haematology</i> , 1997, 99, 933-938.	2.5	70
27	Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency. <i>Blood</i> , 2018, 131, 917-931.	1.4	68
28	Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity. <i>Blood</i> , 2014, 123, 1327-1335.	1.4	63
29	Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2017, 129, 3221-3226.	1.4	61
30	Molecular classification improves risk assessment in adult <i>t(12;21)(p13;q22)</i> -negative B-ALL. <i>Blood</i> , 2021, 138, 948-958.	1.4	59
31	Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma. <i>Blood</i> , 2010, 115, 2763-2768.	1.4	58
32	Incidence and Dynamics of Epstein-Barr Virus Reactivation After Alemtuzumab-Based Conditioning for Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Transplantation</i> , 2010, 90, 564-570.	1.0	57
33	HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning. <i>Blood</i> , 2010, 115, 5147-5153.	1.4	56
34	The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and <i>t(4;11)(q21;q23)/MLL-AFF1</i> prospectively treated in the UKALLXII/ECOG2993 trial. <i>Haematologica</i> , 2013, 98, 945-952.	3.5	54
35	A Hyperfusogenic Gibbon Ape Leukemia Envelope Glycoprotein: Targeting of a Cytotoxic Gene by Ligand Display. <i>Human Gene Therapy</i> , 2000, 11, 817-826.	2.7	51
36	Characterisation of the genomic landscape of <i>CRLF2</i> -rearranged acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 363-372.	2.8	49

#	ARTICLE	IF	CITATIONS
37	Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA). <i>Blood</i> , 2015, 126, 679-679.	1.4	39
38	Measles as a potential oncolytic virus. <i>Reviews in Medical Virology</i> , 2005, 15, 135-142.	8.3	38
39	Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. <i>Haematologica</i> , 2009, 94, 1399-1406.	3.5	34
40	Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2013, 160, 640-648.	2.5	33
41	Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2010, 95, 8-12.	3.5	26
42	Impact of Pretransplantation 18 F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1234-1241.	2.0	26
43	Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study. <i>Leukemia</i> , 2022, 36, 625-636.	7.2	25
44	Mouse xenograft modeling of human adult acute lymphoblastic leukemia provides mechanistic insights into adult LIC biology. <i>Blood</i> , 2014, 124, 96-105.	1.4	24
45	Phase I Study of High-Stringency CD8 Depletion of Donor Leukocyte Infusions After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation</i> , 2009, 88, 1312-1318.	1.0	23
46	Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 594-602.	3.3	23
47	Differential Cytopathology and Kinetics of Measles Oncolysis in Two Primary B-cell Malignancies Provides Mechanistic Insights. <i>Molecular Therapy</i> , 2011, 19, 1034-1040.	8.2	22
48	JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2018, 215, 1929-1945.	8.5	22
49	Does Imatinib Change the Outcome in Philadelphia Chromosome Positive Acute Lymphoblastic Leukaemia in Adults? Data from the UKALLXII/ECOG2993 Study.. <i>Blood</i> , 2007, 110, 8-8.	1.4	22
50	Attenuated, Oncolytic, but Not Wild-Type Measles Virus Infection Has Pleiotropic Effects on Human Neutrophil Function. <i>Journal of Immunology</i> , 2012, 188, 1002-1010.	0.8	20
51	Monitoring MRD in ALL: Methodologies, technical aspects and optimal time points for measurement. <i>Seminars in Hematology</i> , 2020, 57, 142-148.	3.4	20
52	Type 1 Interferon Responses Underlie Tumor-Selective Replication of Oncolytic Measles Virus. <i>Molecular Therapy</i> , 2020, 28, 1043-1055.	8.2	18
53	Successful remission induction therapy with gilteritinib in a patient with <i>de novo</i> FLT3-mutated acute myeloid leukaemia and severe COVID-19. <i>British Journal of Haematology</i> , 2020, 190, e189-e191.	2.5	17
54	Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 3033-3037.	5.2	16

#	ARTICLE	IF	CITATIONS
55	Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial. <i>Lancet Haematology</i> , 2022, 9, e262-e275.	4.6	14
56	Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial. <i>Blood</i> , 2010, 116, 169-169.	1.4	13
57	Philadelphia-Positive Acute Lymphoblastic Leukemia—Is Bone Marrow Transplant Still Necessary?. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S84-S88.	2.0	12
58	The Role of Neutrophils in Measles Virus-mediated Oncolysis Differs Between B-cell Malignancies and Is Not Always Enhanced by GCSF. <i>Molecular Therapy</i> , 2016, 24, 184-192.	8.2	12
59	Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence study. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 523-533.	1.4	12
60	Quality-of-life issues and symptoms reported by patients living with haematological malignancy: a qualitative study. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072095500.	2.5	12
61	Single nucleotide polymorphism array-based signature of low hypodiploidy in acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 604-615.	2.8	12
62	Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 7005-7005.	1.6	12
63	First Analysis of the UKALL14 Randomized Trial to Determine Whether the Addition of Nelarabine to Standard Chemotherapy Improves Event Free Survival in Adults with T-Cell Acute Lymphoblastic Leukaemia (CRUK/09/006). <i>Blood</i> , 2021, 138, 366-366.	1.4	12
64	In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial. <i>Lancet Haematology</i> , 2022, 9, e276-e288.	4.6	12
65	CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy. <i>Blood Advances</i> , 2020, 4, 4665-4668.	5.2	11
66	First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine If the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (CRUK/09/006). <i>Blood</i> , 2019, 134, 739-739.	1.4	11
67	Recent Developments in the Management of T-Cell Precursor Acute Lymphoblastic Leukemia/Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 160-169.	2.3	10
68	Antigen receptor gene rearrangements reflect on the heterogeneity of adult Acute Lymphoblastic Leukaemia (ALL) with implications of cell origin of ALL subgroups—a UKALLXII study. <i>British Journal of Haematology</i> , 2010, 148, 394-401.	2.5	9
69	Oncolytic Measles Virotherapy and Opposition to Measles Vaccination. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1834-1839.	3.0	9
70	Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity. <i>Frontiers in Pharmacology</i> , 2020, 11, 209.	3.5	9
71	Feasibility Of Pegylated-Asparaginase (PEG-ASP) During Induction In Adults With Acute Lymphoblastic Leukaemia (ALL): Results From The UK Phase 3 Multicentre Trial UKALL 14. <i>Blood</i> , 2013, 122, 3900-3900.	1.4	9
72	Fludarabine, Melphalan and Alemtuzumab Conditioned Reduced Intensity (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults Aged >40 Years with De Novo Acute Lymphoblastic Leukemia: A Prospective Study from the UKALL14 Trial (ISRCTN 66541317). <i>Blood</i> , 2015, 126, 733-733.	1.4	9

#	ARTICLE	IF	CITATIONS
73	Response: Chemotherapy or allografting for young adults with high-risk ALL?. Blood, 2008, 111, 5755-5755.	1.4	8
74	In Adults with Standard-Risk Acute Lymphoblastic Leukemia (ALL) the Greatest Benefit Is Achieved from an Allogeneic Transplant in First Complete Remission (CR) and an Autologous Transplant Is Less Effective Than Conventional Consolidation/Maintenance Chemotherapy: Final Results of the International ALL Trial (MRC UKALL XII/ECOG E2993).. Blood, 2006, 108, 2-2.	1.4	8
75	Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. American Journal of Hematology, 2016, 91, 1107-1112.	4.1	7
76	<i>IKZF1</i> alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trial. Blood Advances, 2021, 5, 3322-3332.	5.2	7
77	Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study. Frontiers in Pharmacology, 2020, 11, 1308.	3.5	7
78	Prognostic Impact of Chromosomal Abnormalities and Copy Number Alterations Among Adults with B-Cell Precursor Acute Lymphoblastic Leukaemia Treated on UKALL14. Blood, 2019, 134, 288-288.	1.4	6
79	Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (B-ALL) Patients (pts) From the International UKALLXII/E2993 Trial: No Difference In Results Between B Cell Immunophenotypic Subgroups. Blood, 2010, 116, 524-524.	1.4	6
80	An Evaluation of Molecular Response in a Phase 2 Open-Label, Multicenter Confirmatory Study in Patients (pts) with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Receiving Treatment with the BiTE [®] Antibody Construct Blinatumomab. Blood, 2014, 124, 3704-3704.	1.4	6
81	Allogeneic Hematopoietic Stem Cell Transplantation Following Anti-CD19 BiTE [®] Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 965-965.	1.4	6
82	Development of a Novel Patient-Reported Outcome Measure in Haematological Malignancy for Use in Routine Clinical Practice: Item Generation. Blood, 2016, 128, 5985-5985.	1.4	6
83	SSBP2-CSF1R Is a Recurrent Fusion in B-Other Acute Lymphoblastic Leukaemia with Variable Clinical Outcome. Blood, 2014, 124, 3773-3773.	1.4	5
84	High Frequency and Poor Outcome of Ph-like Acute Lymphoblastic Leukemia in Adults. Blood, 2015, 126, 2618-2618.	1.4	5
85	Peripheral Blood Progenitor Cells Versus Bone Marrow. Stem Cells and Development, 1994, 3, 299-304.	1.0	4
86	Molecular Monitoring of Residual Disease (MRD) during Induction and Intensification Phases in Low Risk Adult B Cell ALL Treated According to the MRC UKALL12 Protocol.. Blood, 2005, 106, 1466-1466.	1.4	4
87	Comparative analysis of melphalan versus busulphan cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia. British Journal of Haematology, 2019, 187, e20-e24.	2.5	3
88	Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO. Frontiers in Pharmacology, 2020, 11, 571066.	3.5	3
89	Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial. Blood, 2010, 116, 493-493.	1.4	3
90	Antibody responses to SARS-CoV-2 vaccination in patients with acute myeloid leukaemia and high risk MDS on active anti-cancer therapies. British Journal of Haematology, 2022, 198, 478-481.	2.5	3

#	ARTICLE	IF	CITATIONS
91	Inotuzumab ozogamicin versus FLAG-Ida in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia – real-world resource use data. <i>Leukemia and Lymphoma</i> , 2020, 61, 491-493.	1.3	2
92	Utility of 18F-FDG-PET/CT in lymphoblastic lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1010-1012.	1.3	2
93	The Value of Molecular Monitoring for Residual Disease (MRD) in Early Morphological Remitters among Adults Diagnosed with B Cell ALL and Treated According to the MRC UKALL12 Protocol. <i>Blood</i> , 2005, 106, 1467-1467.	1.4	2
94	The Impact of Imatinib Therapy on Adult Philadelphia Positive Acute Lymphoblastic Leukaemia (ALL): Early Results from the UKALL12/ECOG 2993 Study. <i>Blood</i> , 2005, 106, 1839-1839.	1.4	2
95	Utility of FDG-PET/CT in Lymphoblastic Lymphoma. <i>Blood</i> , 2019, 134, 2890-2890.	1.4	2
96	En-Abl-ing treatment of ‘Ph-like’ ALL?. <i>Blood</i> , 2019, 134, 1277-1278.	1.4	1
97	Editors’ Introduction to special issue. <i>British Journal of Haematology</i> , 2020, 191, 519-520.	2.5	1
98	Single Nucleotide Polymorphism Array-Based Signature of Genetic Ploidy Groups in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 1473-1473.	1.4	1
99	Genetic and Genomic Characterisation of Older Adults with Acute Lymphoblastic Leukemia Treated on the UKALL14 and UKALL60+ Clinical Trials. <i>Blood</i> , 2019, 134, 2746-2746.	1.4	1
100	Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993). <i>Blood</i> , 2008, 112, 3314-3314.	1.4	1
101	Karyotype Is an Independent Prognostic Factor in Adult Acute Lymphoblastic Leukaemia (ALL): Analysis of Cytogenetic Data from 1,235 Patients on the Medical Research Council (MRC) UKALLXII /Eastern Cooperative Oncology Group (ECOG) 2993 Trial. <i>Blood</i> , 2005, 106, 331-331.	1.4	1
102	An Optimised In Vivo Modelling System For Adult Acute Lymphoblastic Leukaemia (ALL) Enables Sensitive Detection Of Leukaemia Initiating Cells (LIC) and Drug Resistant Clones. <i>Blood</i> , 2013, 122, 2641-2641.	1.4	1
103	Pre-Transplantation FDG-PET Predicts Early but Not Late Survival Outcomes Following Allogeneic Transplantation in Chemo-Sensitive Hodgkin Lymphoma. <i>Blood</i> , 2014, 124, 1225-1225.	1.4	1
104	Delays in Start of Intensification Therapy Are Common for Adults with Acute Lymphoblastic Leukemia, and Are Associated with Decreased Survival in Patients Who Undergo Allogeneic Stem Cell Transplant (SCT). <i>Blood</i> , 2014, 124, 208-208.	1.4	1
105	Final Development of the First Generic Quality of Life and Symptoms Measure Specific for Hematological Malignancies: The HM-PRO. <i>Blood</i> , 2019, 134, 3484-3484.	1.4	1
106	Acute lymphoblastic leukaemia (ALL) things come to those who wait: 60 years of progress in the treatment of adult ALL. <i>British Journal of Haematology</i> , 2020, 191, 558-561.	2.5	1
107	JAK-ing up treatment for CRLF2-R ALL. <i>Blood</i> , 2022, 139, 645-646.	1.4	1
108	Be careful what you wish for?. <i>Blood</i> , 2007, 109, 2673-2674.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Delays in Intensification are Common in Adults with Acute Lymphoblastic Leukemia (ALL), are Associated with Decreased Survival in Allogeneic Hematopoietic Cell Transplant (HCT) Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S176-S177.	0.4	0
110	65. Oncolytic Measles Virus Differentially Affects Mitochondrial Biogenesis in Transformed versus Non-Transformed BM-Derived MSCs. <i>Molecular Therapy</i> , 2016, 24, S28-S29.	8.2	0
111	663. Can Oncolytic Measles Virus Targeted to CD20 Recapitulate Any of the Effects of Rituximab in the Treatment of Acute Lymphoblastic Leukemia?. <i>Molecular Therapy</i> , 2016, 24, S262-S263.	8.2	0
112	ARF way to Ph+ ALL stratification?. <i>Blood</i> , 2018, 131, 1394-1395.	1.4	0
113	Value of Molecular Monitoring for Minimal Residual Disease Preceding Autologous SCT Following Diagnosis of B Cell Acute Lymphoblastic Leukemia in Patients Treated with the MRC UKALL12 Protocol.. <i>Blood</i> , 2005, 106, 1468-1468.	1.4	0
114	T-Cell Depleted Unrelated Donor Stem Cell Transplants Appear to Be of Value for Adult Philadelphia Chromosome Negative ALL Patients and Should Be Evaluated Prospectively in New Large Group Studies. <i>Blood</i> , 2008, 112, 4413-4413.	1.4	0
115	Attenuated Measles Virus: A Promising Therapeutic Modality for B Cell Malignancy.. <i>Blood</i> , 2009, 114, 2460-2460.	1.4	0
116	Vaccine Measles Virus Has Therapeutic Potential In B Cell Malignancy.. <i>Blood</i> , 2010, 116, 3757-3757.	1.4	0
117	Positive Pre-Transplantation [18-F] FDG-PET Is Not a Barrier to Successful Allograft Outcomes in Chemosensitive Hodgkin Lymphoma. <i>Blood</i> , 2011, 118, 2016-2016.	1.4	0
118	Biology and Outcome of 85 Adults with Acute Lymphoblastic Leukemia (ALL) with t(4;11)/MLL-AF4 Treated in the UKALL XII/ECOG 2993 Study. <i>Blood</i> , 2012, 120, 663-663.	1.4	0
119	Evaluation Of IKZF1 \hat{r} 4-7 Deletion As a Suitable Marker For Minimal Residual Disease Monitoring; A Study Of 161 Consecutive Acute Lymphoblastic Leukaemia (ALL) Patients On The On-Going UKALL14 Trial. <i>Blood</i> , 2013, 122, 1335-1335.	1.4	0
120	Barriers To Clinical Trial Enrolment For Teenagers and Young Adults With Acute Lymphoblastic Leukaemia: The Impact of Age Eligibility Criteria. <i>Blood</i> , 2013, 122, 1401-1401.	1.4	0
121	TP53 Alterations Are Frequent in Patients over 60 Years with B-Precursor Acute Lymphoblastic Leukemia (ALL) and Low Hypodiploid/Near Triploid (HoTr) Karyotype; They Correlate with RB1 Deletion and Leukemic Telomere Gain. <i>Blood</i> , 2014, 124, 3801-3801.	1.4	0
122	in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993. <i>Blood</i> , 2015, 126, 795-795.	1.4	0
123	Successful Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation in Adults with Inherited Primary Immunodeficiency (PID). <i>Blood</i> , 2016, 128, 4681-4681.	1.4	0
124	Activation of the LMO2 Oncogene in T-ALL through a Somatic Acquired Neomorphic Promoter. <i>Blood</i> , 2016, 128, 733-733.	1.4	0
125	Commonly Used Chemotherapy Drugs Differentially Determine Microenvironment-Mediated Protection, Via Mitochondrial Transfer, to B-Precursor Acute Lymphoblastic Leukaemia Cells. <i>Blood</i> , 2018, 132, 2690-2690.	1.4	0
126	Whole Genome Profiling of Adult B-Other Acute Lymphoblastic Leukaemia on the UKALL14 Trial. <i>Blood</i> , 2019, 134, 2743-2743.	1.4	0